Analysts Issue Forecasts for DMAC Q1 Earnings

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of DiaMedica Therapeutics in a research report issued on Monday, November 17th. HC Wainwright analyst M. Caufield forecasts that the company will post earnings of ($0.18) per share for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for DiaMedica Therapeutics’ current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics’ Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.22) EPS and FY2029 earnings at $0.15 EPS.

DMAC has been the topic of several other research reports. TD Cowen initiated coverage on shares of DiaMedica Therapeutics in a research note on Thursday, October 30th. They issued a “buy” rating on the stock. Cowen began coverage on DiaMedica Therapeutics in a research report on Thursday, October 30th. They issued a “buy” rating on the stock. Wall Street Zen lowered DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Wednesday, October 8th. Finally, Cantor Fitzgerald initiated coverage on DiaMedica Therapeutics in a report on Friday. They set an “overweight” rating on the stock. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, DiaMedica Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $12.33.

DiaMedica Therapeutics Stock Performance

Shares of NASDAQ:DMAC opened at $6.41 on Tuesday. The firm has a market cap of $333.81 million, a price-to-earnings ratio of -9.29 and a beta of 1.42. The firm has a fifty day moving average price of $6.76 and a 200 day moving average price of $5.28. DiaMedica Therapeutics has a fifty-two week low of $3.19 and a fifty-two week high of $7.49.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02).

Insider Buying and Selling

In related news, major shareholder Jan Stahlberg acquired 338,265 shares of DiaMedica Therapeutics stock in a transaction on Monday, August 25th. The shares were bought at an average cost of $6.00 per share, with a total value of $2,029,590.00. Following the completion of the purchase, the insider directly owned 7,654,045 shares of the company’s stock, valued at $45,924,270. The trade was a 4.62% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders bought a total of 627,752 shares of company stock valued at $3,752,239 in the last ninety days. Company insiders own 7.30% of the company’s stock.

Hedge Funds Weigh In On DiaMedica Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of DMAC. Strs Ohio raised its holdings in DiaMedica Therapeutics by 19.7% during the 3rd quarter. Strs Ohio now owns 9,100 shares of the company’s stock valued at $63,000 after buying an additional 1,500 shares during the period. World Investment Advisors increased its position in DiaMedica Therapeutics by 7.3% during the third quarter. World Investment Advisors now owns 34,325 shares of the company’s stock valued at $236,000 after acquiring an additional 2,350 shares during the last quarter. Rhumbline Advisers raised its stake in shares of DiaMedica Therapeutics by 14.5% in the third quarter. Rhumbline Advisers now owns 27,357 shares of the company’s stock valued at $188,000 after acquiring an additional 3,463 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of DiaMedica Therapeutics by 24.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 18,882 shares of the company’s stock worth $74,000 after acquiring an additional 3,709 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of DiaMedica Therapeutics by 44.2% in the 3rd quarter. Bank of America Corp DE now owns 12,249 shares of the company’s stock worth $84,000 after acquiring an additional 3,752 shares during the last quarter. Hedge funds and other institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.